Adderall‑Induced Jaw Clenching and Facial Muscle Tension

Clinical Presentation

Facial muscle tightness and occasional grimacing/frowning have been reported in patients receiving mixed amphetamine salts, reflecting increased mandibular muscle tone【1】.

Amphetamine‑related jaw clenching should be distinguished from acute dystonia, which typically involves rapid, involuntary spasms of the face, eyes, and neck and is more commonly linked to antipsychotic agents【1】.

Reducing the daily dose of Adderall is the first‑line strategy for alleviating muscle tension and bruxism, as these adverse effects are dose‑dependent【2】.

Switching from immediate‑release to extended‑release (ER) formulations can lessen peak plasma concentrations that exacerbate muscle tension, thereby improving tolerability【3】.
ER products exhibit a smoother ascending concentration profile with lower peaks compared with immediate‑release tablets, supporting reduced sympathomimetic side effects【4】.

When muscle tension persists despite dose optimization, transitioning to a non‑stimulant such as atomoxetine (60–100 mg daily) is an option; atomoxetine shows medium‑range effect sizes (≈0.7) versus stimulants (≈1.0)【5】.
Extended‑release guanfacine or clonidine may be employed as adjunctive or alternative agents, particularly in patients with comorbid tics or prominent muscle tension【5】.

Clinicians should assess for jaw‑clenching or facial muscle tension at every follow‑up visit, especially during dose titration phases【3】.
Ongoing evaluation for progression to more severe movement disorders (e.g., dystonia) is recommended, with prompt referral if such signs emerge【1】.
A systematic benefit‑risk assessment should be performed, recognizing that mild muscle tension may be acceptable when ADHD symptom control is optimal【3】.

Discontinuing Adderall abruptly without first attempting dose reduction often leads to unnecessary loss of therapeutic benefit; dose adjustment usually resolves the muscle‑tension symptoms【3】.
Misidentifying amphetamine‑induced muscle tension as antipsychotic‑related dystonia can result in inappropriate treatment; the two conditions have distinct clinical features【1】.
Escalating the dose in an attempt to “override” muscle tension typically worsens sympathomimetic adverse effects and should be avoided【3】.